Navigation Links
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Date:1/31/2008

ell counts, including leukopenia (low white blood cell count), thrombocytopenia (low platelet count) and neutropenia (low neutrophil count); thyroiditis (inflammation of the thyroid gland); and autoimmunity (production of antibodies against the body's own tissues.)

Depression and suicidal behavior, including suicidal ideation, suicidal attempts and completed suicides, have been reported in association with treatment with alfa interferons.

Important Safety Information Regarding U.S. Labeling for PEGINTRON(TM) Alpha interferons, including PEGINTRON(TM) and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON(TM) and/or INTRON(R) A therapy.

Contraindications

PEGINTRON(TM) is contraindicated in patients with hypersensitivity to PEGINTRON(TM) or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score >6 [class B and C]) in cirrhotic CHC patients before or during treatment. INTRON(R) A (Interferon alfa-2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON(R) A or any component of the product, autoimmune hepatitis, and decompensated liver disease.

Incidence of adverse events

There are no new adverse events specific to PEGINTRON(TM) as compared to INTRON(R) A; however, the incidence of some (eg, injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON(TM) were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all wer
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
(Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
(Date:6/1/2015)... 2015  The Val Skinner Foundation is partnering with ... for high school students focused on cancer genetics. Skinner ... LIFE Event (LPGA Pros in the Fight to Eradicate ... West Caldwell, N.J. ... more than $500,000 on Monday, bringing the foundation,s 16-year ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Val Skinner Foundation Announces Partnership With Discovery Education 2
... the job market is showing a pulse again, Midwest technology ... employee is going to surprise them with a resignation letter ... two-week notice period? , ,Nice as it is to see ... manager whos on the hook to deliver a new product, ...
... five more Wisconsin companies qualify for tax credits under ... assistance to start-up companies, Governor Jim Doyle said on Friday. ... investors to claim tax credits after financing technology firms from ... , ,Most companies on the list are in the life ...
... students will get a one-of-a-kind experience today when they ... Space Station Expedition 10 crew. , ,The event will ... at Crossroads Elementary School, St. Paul, Minn. The event ... and Flight Engineer Salizhan Sharipov. Nearly 700 students in ...
Cached Biology Technology:Keep your tech employees happy 2Keep your tech employees happy 3Keep your tech employees happy 4
(Date:6/1/2015)... -- According to a new market ... (Government, Military & Defense, Healthcare, Banking & Finance, ... (Face Recognition, Fingerprint Recognition, Iris Recognition, Palm Recognition, ... Function (Contact and Non-Contact) & Geography ( ... , APAC, Row) - Global Forecast to 2020", ...
(Date:5/26/2015)... , May 26, 2015 ... announced the addition of the "Saudi Arabia ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Arabia is projected to grow at ... high growth is attributed to the surging demand ...
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
Breaking Biology News(10 mins):Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4
... - The American Society for Neural Therapy and ... May 1st, 2010 in Clearwater Beach, Florida, has awarded ... to Shinn-Zong Lin, MD, PhD, professor of neurosurgery at ... Hospital, Taichung, Taiwan. The award was presented in recognition ...
... transgenic mouse to display the earliest signs of Parkinson,s disease ... forms of the disease. The mouse model, which expresses ... early signs of constipation and other gastrointestinal problems that are ... As a result, researchers say, these animals could serve as ...
... In 1985 there was little hope for people with ... of emaciated figures dying from a disease that had no ... Institutes of Health,s National Cancer Institute announced it had come ... drugs discovered by this group followed. A quarter-century later in ...
Cached Biology News:ASNTR meeting presents Sanberg Awards to Prof. Lin & Prof. Dunnett 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 3Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years 2Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years 3
... agarose-digesting enzyme isolated from Pseudomonas atlantica. ... in agarose producing carbohydrate molecules that ... carbohydrate molecules will not interfere with ... Gelzyme enzyme can be used for ...
... contains the cellular components necessary for protein ... and termination factors) but has not been ... used primarily for the isolation of these ... endogenous globin mRNA. Untreated Lysate is prepared ...
...
...
Biology Products: